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Abstract
Objectives: Metabolic flexibility is defined as ability to adjust fuel oxidation to fuel availability. Multiple sclerosis (MS) results
in reduced muscle strength and exercise intolerance. We tested the hypothesis that altered metabolic flexibility contributes
to exercise intolerance in MS patients.
Methods: We studied 16 patients (all on glatiramer) and 16 matched healthy controls. Energy expenditure (EE), and
carbohydrate (COX) and lipid oxidation (LOX) rates were determined by calorimetry, before and after an oral glucose load.
We made measurements either at rest (canopy device) or during 40 min low-grade (0.5 W/kg) exercise (metabolic chamber).
We also obtained plasma, and adipose tissue and skeletal muscle dialysate samples by microdialysis to study tissue-level
metabolism under resting conditions.
Results: At rest, fasting and postprandial plasma glucose, insulin, and free fatty acid levels did not differ between patients
and controls. Fasting and postprandial COX was higher and LOX lower in patients. In adipose, fasting and postprandial
dialysate glucose, lactate, and glycerol levels were higher in patients vs. controls. In muscle, fasting and postprandial
dialysate metabolite levels did not differ significantly between the groups. During exercise, EE did not differ between the
groups. However, COX increased sharply over 20 min in patients, without reaching a steady state, followed by an immediate
decrease within the next 20 min and fell even below basal levels after exercise in patients, compared to controls.
Conclusions: Glucose tolerance is not impaired in MS patients. At rest, there is no indication for metabolic inflexibility or
mitochondrial dysfunction in skeletal muscle. The increased adipose tissue lipolytic activity might result from glatiramer
treatment. Autonomic dysfunction might cause dysregulation of postprandial thermogenesis at rest and lipid mobilization
during exercise.
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Introduction
Multiple sclerosis (MS) is the most common non-traumatic
autoimmune neurological disease among young adults. MS is
characterized by focal lymphocytic infiltration leading to demy-
elination and neuroaxonal loss. [1] Irreversible neuroaxonal
damage results in a wide range of symptoms, including complex
functional impairments such as abnormal walking mechanics, poor
balance, muscle weakness, and exercise intolerance. [2] Altered
mitochondrial function may contribute to the pathogenesis of
axonal damage in MS. However, the data are primarily derived
from studies on animal models or post mortem investigations in MS
patients. In experimental autoimmune encephalomyelitis (EAE),
mitochondrial dysfunction plays a pivotal role in axonal degen-
eration. [3] Recently, Nikic´ et al. suggested that demyelination
may not be a prerequisite for axon damage, as commonly
believed. Instead, they suggested focal intra-axonal mitochondrial
pathology precedes changes in axon morphology in EAE. [4]
Reduced respiratory chain complex IV activity has been observed
within demyelinated axons in MS patients. [5,6] In Huntingtons
disease, faulty complex I activity, as well as other deficits in muscle
mitochondrial oxidative metabolism have been observed. [7,8]
Furthermore, investigators recorded increased energy expenditure
during both fasting and hyperinsulinemic-euglycemic conditions.
[9] Interestingly, extra-mitochondrial glucose metabolism in the
CNS is increased in MS and is associated with disease progression.
[10] A recent study reported significantly reduced complex I
activity in freshly isolated mitochondria from skeletal muscle in
Persian MS patients. [11].
Central and peripheral mitochondrial dysfunction should affect
the regulation of systemic and local energy metabolism at rest,
postprandially or during exercise. Mitochondrial dysfunction
might also impair metabolic flexibility, i.e. the capacity to utilize
lipid and carbohydrate fuels and to transition between the two
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oxidative fuel sources and therefore the ability to adjust fuel
oxidation to fuel availability. [12] Therefore, we tested the
hypothesis that metabolic flexibility is reduced in MS patients.
We reasoned that a reduced metabolic flexibility might contribute
to exercise intolerance above-and-beyond neural dysfunction.
Impaired oxidative metabolism due to altered mitochondrial
function results in increased lactate production and an elevated
lactate/pyruvate ratio. [13,14] Alternatively, an impaired function
of the autonomic nervous system might also impair substrate
mobilization and hence contribute to exercise intolerance.
Metabolic flexibility is mostly assessed by testing the switch from
fat to carbohydrate oxidation 1) within an euglycemic hyperinsu-
linemic clamp or during overnight fasting (short-term), or 2)
during a 3–7 d high-carbohydrate or high-fat diet (long-term),
both combined with calorimetric measurements in order to assess
changes in carbohydrate and lipid oxidation rates. [15] We relied
on a standardized protocol that we designed to study metabolic
alterations in patients with lipodystrophy. [16,17].
Methods
Subjects
We recruited 16 consecutive patients with relapsing-remitting
MS according to the 2005 panel criteria. [18] We also identified
16 healthy control subjects closely matched for gender, age, and
body mass index (Fig. 1). The two groups did not differ
significantly regarding demographic and anthropometric charac-
teristics (Table 1). The institutional review board of Charite´
University Medicine Berlin approved the study and written
informed consent was obtained from all participants prior study
entry. Key inclusion criteria for MS patients were a stable
immune-modulating, neuroprotective therapy with glatiramer for
at least 12 months and an Extended Disability Status Scale (EDSS)
score ,5 but no other medication. [19].
Protocol
After a 12 h overnight fast, a catheter was placed in a large
antecubital vein for blood sampling. One microdialysis probe
(CMA/60, Dipylon Medical AB, Solna, Sweden) each was
inserted into abdominal subcutaneous adipose tissue and Vastus
lateralis muscle. [16,17] After probe insertion, tissue perfusion was
started with lactate free Ringer’s solution supplemented with
50 mmol/L ethanol at a flow rate of 2 mL/min using CMA/102
microdialysis pumps. Ethanol was added to assess changes in tissue
perfusion by using the ethanol dilution technique. [20,21] After a
recovery period of at least 60 min, a 75 g oral glucose load (OGL)
was given (300 ml solution, DextroH, O.G.T., Hoffmann-La
Roche AG, Grenzach-Wyhlen, Germany). Blood and dialysate
samples were taken at baseline and every 15 min over 2 h after
glucose. Carbon dioxide (CO2) production and oxygen (O2)
consumption were measured by a canopy calorimeter (DeltatracII,
Datex Ohmeda, Duisburg, Germany) in the supine position to
calculate resting and postprandial energy expenditure (EE) and
respiratory quotient (RQ = VCO2/VO2). The RQ can be used
to assess changes in carbohydrate and lipid oxidation rates. Energy
expenditure and substrate oxidation rates were calculated accord-
ing the equations proposed by Ferrannini. [22].
Twelve MS patients and 12 healthy controls, closely matched
for gender, age and body weight were able to perform
standardized exercise in a metabolic chamber (Fig. 1). To further
minimize a possible bias between the groups, patients and healthy
controls were additionally matched for body composition (fat mass
and fat-free mass) and physical activity level. Body composition
was determined by measuring body weight and body volume by
using an Air-Displacement Plethysmograph (Bod Pod, Life
Measurements, Inc., Concord, CA). All participants completed a
questionnaire asking for work, leisure, and sports activities within
the preceding year. [23] Then, resting EE per hour was predicted
according to the equations by Mu¨ller et al. [24] for normal weight
subjects and the respective values were multiplied by energy cost
and duration (h/wk) of the respective activity (Table 1). [25].
The metabolic chamber is a comfortable, airtight room (width:
2.5 m, depth: 2.0 m, height: 2.2 m) that is constantly supplied with
fresh air like an open circuit indirect calorimeter. Measurements
and calculations were the same as for the canopy calorimeter. In
previous studies on 16 healthy subjects, the maximum spontaneous
change in metabolic rate over a 3 h period was 0.260.09 kJ/min
(3%). While being seated in a comfortable chair, measurements
were started at first for air equilibration (30 min) and then for
calculating subjects resting EE (40 min). Then, a 75-g oral glucose
load was given. After 15 min, subjects started exercising over
40 min on a bicycle ergometer (VIAsprint 150 P, Ergoline, Bitz,
Germany) adjusted individually to a workload of 0.5 W/kg body
weight.
Assays
Plasma glucose and insulin concentrations were measured
according to international standards; free fatty acids (FFA) by an
automated colorimetric test (ABX Pentra 400 Chemistry Analyser,
Horiba ABX, Bedfordshire, U.K.).
Perfusate (inflow) and dialysate (outflow) ethanol concentrations
were measured with a standard spectrophotometric enzymatic
assay. A decrease in the ethanol outflow/inflow ratio (‘‘ethanol
ratio’’) is equivalent to an increase in blood flow and vice versa.
[20] Dialysate glucose, lactate, pyruvate, and glycerol concentra-
tions were measured with the CMA/600 analyzer. In situ dialysate
recovery for these metabolites was about 30% in adipose tissue
and 50% in skeletal muscle, respectively, as assessed by near-
equilibrium dialysis. [26].
Statistics
All data was tested for normal distribution using histograms,
Shapiro-Wilk tests and analysis of skewness and kurtosis. Since not
all data were normally distributed, non-parametric tests were
applied in all cases. Owing to this approach, it was not possible to
correct for possible confounders as covariates. Consequently,
patients and controls were closely matched regarding age and
gender. For protocol I, group differences were analysed using
Brunner’s non-parametric analysis for longitudinal data. [27] As
results, group differences and group*time interaction effects from
the ANOVA type model for small sample sizes are given. For
protocol II, group differences were analyzed using Mann-
Whitney-U tests for baseline (0 min) RQ and exercise EE
(40 min). Brunner analysis was performed using R Project 2.14.1
with the macro F1_LD_F1. All other statistical analyses and
graphics were performed with GraphPad Prism (version 5.01). All
data in graphics are shown with mean and standard error of the
mean (SEM). A P value ,0.05 indicated statistical significance. All
tests should be understood as constituting exploratory data
analysis. Therefore, no previous power calculation or adjustments
for multiple testing were made.
Results
Baseline values and postprandial profiles of plasma glucose,
insulin, and FFA concentrations did not differ between the groups
(Fig. 2). Fasting ß-hydroxybutyrate concentrations were 133 (SD,
174) mmol/L in patients and 74 (SD, 57) mmol/L in controls (not
Metabolism in Multiple Sclerosis
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Figure 1. Study design. PAL, physical activity level; BMI, body mass index.
doi:10.1371/journal.pone.0043675.g001
Table 1. Demographic and anthropomorphic characteristics of MS patients and control subjectsa.
Characteristics Protocol I Protocol II
MS CTRL MS CTRL
Men/women (n) 8/8 8/8 6/6 6/6
Age (yrs) 4566 (35–61) 40612 (26–61) 4667 (35–62) 4869 (29–59)
BMI (kg/m2) 25.265.2 (19.1–37.7) 23.262.4 (19.3–29.3) 24.464.7 (19.5–36.3) 23.461.8 (19.3–28.0)
Body fat (%) n/a n/a 31612 (16–50) 26612 (6–39)
Lean body mass (%) n/a n/a 69612 (50–84) 74612 (61–94)
PAL n/a n/a 1.7960.33 (1.37–2.42) 1.7960.15 (1.56–2.16)
Disease duration (yrs) 11.1 (2.4–19.2)b n/a 11.8 (3.5–19.9)b n/a
EDSS (arbitrary units) 2.0 (1.0–4.5)b n/a 2.0 (1.0–4.5)b n/a
aData are given as means 6 SD (total range) unless stated otherwise. BMI denotes body mass index, WHR waist-to-hip ratio, PAL physical activity level, EDSS extended
disability status scale, and n/a not applicable.
bMedian (total range).
doi:10.1371/journal.pone.0043675.t001
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significant). Triacylglycerol concentrations did not differ between
the groups, either before (controls: 101 (SD, 45) mg/dL, patients:
106 (SD, 46) mg/dL) or 2 h after glucose (controls: 89 (SD, 42)
mg/dL, patients: 91 (SD, 49) mg/dL).
EE increased similarly within the first 30 min after glucose.
Then, EE rather continued to increase within the next 30 min in
controls, whereas it started to decrease in patients. However, at no
time point postprandial EE was significantly different in patients
vs. controls (Fig. 3A). Fasting RQ was almost identical between the
groups. In controls, RQ decreased slightly within the first 30 min
after glucose, followed by an increase within the following 15 and
reaching a maximum 45 min after glucose. Then, RQ remained
at that maximum level until the end of testing (Fig. 3B). In patients,
however, RQ increased slightly but immediately within the first
30 min after glucose, followed by a stronger increase within the
next 15 min and reaching a maximum 60 min after glucose.
Then, RQ remained also at that maximum level until the end of
testing (Fig. 3B). At all postprandial time points, RQ values were
significantly higher in patients vs. controls, indicating higher
postprandial carbohydrate oxidation rates (Fig. 3C) and, therefore,
lower lipid oxidation rates (Fig. 3D).
In adipose tissue, baseline ethanol ratio was significantly lower
and therefore tissue perfusion significantly higher in patients vs.
controls (Fig. 4A). After glucose, the ethanol ratio remained rather
unchanged in controls whereas it decreased slightly but not
significantly in patients. At all postprandial time points, ethanol
ratio was significantly higher in patients vs. controls (Fig. 4A).
Fasting dialysate glucose levels were higher and the postprandial
increase was significantly greater in patients vs. controls, obviously
a consequence of the about 2-fold greater tissue perfusion in
patients vs. controls (Fig. 4C). Parallel to the greater glucose
supply, baseline and postprandial dialysate lactate levels were also
significantly higher in patients vs. controls (Fig. 4E). Taking into
account the greater tissue perfusion in patients vs. controls, which
leads not only to an increased substrate (glucose) supply but also
product (lactate) removal, adipose tissue lactate production should
be even higher than indicated by the dialysate levels. [28] In
patients, glucose seems to be converted preferentially to lactate. In
adipose tissue, glucose can be converted either to glycerol-3-
phosphate for triacylglycerol synthesis in a liponeogenic state or to
lactate in a rather lipolytic or insulin-resistant state. Baseline
dialysate glycerol levels were higher in patients vs. controls
(Fig. 4G). After glucose administration, dialysate glycerol levels
decreased in both groups, in patients to a greater extent than in
controls, reaching comparable values at the end of testing (Fig. 4G).
Again, because of the greater tissue perfusion in patients vs.
controls, glycerol production should be much higher than
indicated by the dialysate glycerol levels, indicating a higher
lipolytic state in patients vs. controls.
In skeletal muscle, baseline and postprandial ethanol ratio did
not differ significantly between the groups (Fig. 4B). Within both
groups, ethanol ratio did not change significantly throughout the
test. Thus, tissue perfusion had no influence on postprandial
changes in dialysate marker metabolite levels. Fasting dialysate
marker metabolite levels did not differ significantly between the
groups, and after glucose, dialysate glucose (Fig. 4D), lactate
(Fig. 4F) and pyruvate (data not shown) levels increased and
glycerol levels (Fig. 4H) decreased in a normal way without any
significant differences between the groups. For both groups,
baseline pyruvate concentrations were about 20 mmol/L, and
increased to 70 mmol/L within 120 min after glucose. Although
not significant, both fasting and postprandial dialysate glycerol
levels were slightly higher in patients vs. controls (Fig. 4H).
Figure 2. Systemic responses to oral glucose load. Serum (A)
glucose, (B) insulin, and (C) free fatty acids (FFA) in MS patients (n = 16)
and in control subjects (n = 16) before and after an oral glucose load.
Data are given as means 6 SEM. (Conversion factors to convert to
Metric Units (mg/dL) are as follows: 18.02 for glucose, 0.028 for FFA).
doi:10.1371/journal.pone.0043675.g002
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After beginning exercise, EE increased immediately within the
first 10 min in both groups. EE reached a steady state within the
next 20 min in controls. In contrast, EE continued to increase in
MS patients, although more slowly and was significantly higher
after 40 min of moderate exercise, compared to controls (Fig. 5A).
During the recovery phase, EE returned to baseline levels in both
groups (Fig. 5A). Resting RQ was again slightly higher in patients
vs. controls, indicating a higher carbohydrate and lower lipid
oxidation rate (Fig. 5B). During exercise, RQ and therefore
carbohydrate oxidation, increased more strongly and to higher
values in patients vs. controls during the first 20 min (Fig. 5B).
Whereas the RQ was rather stable in controls between 20 and
30 min of exercise, it started to decrease strongly and immediately
in patients after 20 min of exercise. During the recovery phase,
RQ values decreased in both groups below baseline values and this
to a greater extent in patients vs. controls (Fig. 5B).
Discussion
We tested the hypothesis that metabolic flexibility is reduced in
MS patients. We reasoned that such a state-of-affairs could
contribute to their poor muscle strength, decreased performance,
and exercise intolerance. We studied the metabolic response after
glucose in fasted MS patients and healthy control subjects either at
rest or during exercise. We found that at rest, fasting and
postprandial carbohydrate oxidation was greater in MS patients
compared to controls, while lipid oxidation was reduced. The
postprandial EE was similar between the groups. The lipolytic
activity in adipose tissue both before and after glucose was
increased in MS patients compared to controls, but not in muscle.
During exercise, MS patients exhibited a stronger initial increase
in carbohydrate oxidation compared to controls. This response
was followed by an immediate and rapid increase in lipid
oxidation, without an intermediate metabolic steady state. We
suggest that these abnormal responses could contribute to reduced
physical performance.
Figure 3. Systemic energy metabolism measured by indirect calorimetry (canopy device). (A) Energy expenditure (EE, relative changes),
(B) respiratory quotient (RQ), (C) carbohydrate oxidation (COX) and (D) lipid oxidation (LOX) in MS patients (n = 16) and control subjects (n = 14)
before and after an oral glucose load. The elevated RQ value in MS patients indicates increased carbohydrate oxidation. Data are given as means 6
SEM. Group difference P value in graph, group*time interaction effects for RQ P= 0.0008, COX P= 0.0016, LOX P= 0.0009, all by Brunner analysis.
doi:10.1371/journal.pone.0043675.g003
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A well-balanced interaction between sensory and somatic
neurons is a prerequisite for coordinating and adjusting the
different functions of the human body. At the somatic site, motor
neurons control muscle contraction and visceral neurons the
metabolic and hemodynamic adaptation during any physical
activity. In MS patients, sensory and somatic neurons are
irreversibly damaged leading to the diverse appearance of the
disease. [29] However, muscle weakness, early fatigue and exercise
intolerance are key symptoms in MS patients. During exercise, the
nervous system affects metabolism directly through stimulation of
lipolysis and indirectly through stimulation of muscle contraction,
which in turn is linked to various metabolic adjustments. [30]
Additionally, an impaired function of the nervous system could
differently affect systemic and local tissue metabolism. To date, it is
not clear whether skeletal muscle weakness and fatigue are rather
consequences of denervation and disuse or of any other intrinsic
mechanism.[31–33].
Interestingly, our patients presented a slightly higher carbohy-
drate oxidation rate than controls after a 12 h overnight fast. This
result could be a consequence of greater glycogen stores or a
reduced resting metabolic rate with impaired lipid mobilization
and oxidation. However, resting metabolic rate was comparable
between the groups. Shortly after glucose, healthy controls
responded with a decrease in RQ and, therefore, increase in lipid
oxidation as a consequence of an increased sympathetic activity
due to gastric distension. [34] Then, RQ increased as expected,
due to an increase in carbohydrate oxidation. However, we did
not observe an initial RQ decrease in patients. Instead, the RQ
began to increase immediately after glucose and finally reached
much higher values when compared to controls. Postprandial
(diet-induced) thermogenesis is also mediated partly by sympa-
thetic activation. Although not significant, postprandial thermo-
genic response was slightly blunted in our patients. Both, a higher
carbohydrate oxidation rate and a blunted thermogenic response
after glucose could result from autonomic dysfunction. [35,36]
Autonomic dysfunction is a common phenomenon in MS patients.
Particularly affected are bladder, bowel, cardiovascular function,
sleep, sexual and sweat organs. [37] Accordingly, overall metabolic
regulation could also be affected in MS patients.
Postprandial RQ values were not only higher at rest but also
during a subsequent bicycle exercise over 40 min at a moderate
intensity in patients vs. controls, although the difference was not
significant. Interestingly, the increase in RQ was also immediate in
patients vs. controls after starting bicycling, followed by a prompt
decrease after reaching the maximum, even below resting values
during the recovery period. During exercise, normally a mixture of
carbohydrates/lipids is used for fuelling the increased energy
production. The higher the intensity the greater is the carbohy-
drates-to-lipids ratio used as substrate for energy production.
According to the glucose-fatty acid cycle by Randle et al. [38],
fatty acids reduce glucose oxidation and vice versa. At low
intensity exercise, normally lipids contribute significantly to energy
production. Lipid mobilization and oxidation are regulated by the
sympathetic nervous system. Our data indicate a delayed
sympathetic activation and lipid mobilization. However, at least
at the end of exercise, energy expenditure was higher in patients
vs. controls indicating a reduced degree of effectiveness of muscle
work in patients even at low but standardized work load (0.5 W/
kg body weight). This difference might increase further with higher
exercise duration or intensity.
The so far discussed abnormalities in MS patients energy
metabolism do not indicate an altered metabolic flexibility due to
mitochondrial dysfunction. In primary cultured myotubes estab-
lished from healthy lean and obese type 2 diabetics, the variation
in intramyocellular lipid oxidation in vitro was inversely related
with fasting RQ in vivo of all subjects. [39] Also, within a stable
energetic background, an increased mitochondrial mass in human
myotubes was not directly correlated to an increased substrate
oxidation as expected from skeletal muscle in vivo but, surprisingly,
with a reduced complete lipid oxidation. Furthermore, physical
Figure 4. Adipose tissue and skeletal muscle microdialysis. (A, B) Ethanol ratio and dialysate concentrations of (C, D) glucose, (E, F) lactate,
and (G, H) glycerol in adipose tissue and skeletal muscle in MS patients (adipose, n = 15; muscle, n = 16) and in control subjects (n = 16) before and
after an oral glucose load. Data are given as means 6 SEM. P values in graphs indicate group differences; group*time interaction effects were
significant in adipose for lactate (P= 0.0225) and glycerol (P= 0.0001), all by Brunner analysis.
doi:10.1371/journal.pone.0043675.g004
Figure 5. Systemic energy metabolism measured by indirect
calorimetry (metabolic chamber). (A) Energy expenditure (EE) and
(B) respiratory quotient (RQ) in MS patients (n = 12) and control subjects
(n = 12) at rest and during bicycle exercise after an oral glucose load
(OGL). EE after 40 min of exercise P= 0.0243, by Mann-Whitney-U test.
doi:10.1371/journal.pone.0043675.g005
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inactivity decreases mitochondrial content and oxidative capacity
of skeletal muscles in vivo. [40] However, in our study, ambulatory
patients were included with a median EDSS of 2.0 and normal to
moderately impaired mobility. Sedentary controls were closely
matched for physical activity level. Since activity during work and
leisure did not differ between the groups our findings cannot
entirely be explained by reduced physical activity in the MS
patients. Also, lean body mass of our patients was slightly lower
(25%) than in controls which is in line with another study. [41]
The immediate increase in RQ, and therefore carbohydrate
oxidation after the glucose load at rest and during exercise argues
against impaired metabolic flexibility due to mitochondrial
dysfunction.
The results regarding the systemic metabolic response to glucose
were partly confirmed by our data regarding the local hemody-
namic and metabolic response of adipose tissue and skeletal muscle
to glucose while resting. In skeletal muscle, dialysate glucose
increased about 2.5-fold, dialysate lactate about 2-fold, and
dialysate pyruvate about 3-fold after glucose. Baseline and
postprandial tissue perfusion did not differ between the groups.
Hence, skeletal muscle oxidative glucose metabolism should be
unaffected in MS patients as incited by our calorimetric
observations. This finding implies also a proper function of the
respiratory chain, especially of complex I, which is very important
for carbohydrate oxidation. Defects in complex I of the
mitochondrial respiratory chain as reported in Huntingtons
disease seem to be rather unlikely in MS patients at least at a
median EDSS score of 2.0. [7,8] However, we looked just at the
metabolic response after glucose either at rest or during exercise.
The picture might differ when studying muscle metabolism under
fasting conditions during exercise. In adipose tissue, we observed a
rather lipolytic state, indicated by higher baseline and postprandial
dialysate glycerol levels and also higher postprandial dialysate
lactate levels. This might indicate a local insulin resistance. In a
recent study on obese patients we found that systemic monocyte
activation is associated with tissue-specific changes in glucose and
lipid metabolism which may be explained in part by monocyte/
macrophage infiltration of adipose tissue which appears to
interfere with local insulin responsiveness. [17] Systemic and local
monocyte activation is a common feature of both MS and obese/
diabetic patients. [42] The chronic inflammatory process in MS
patients might affect specifically adipose tissue metabolism.
However, we have not tested for that. Instead, is has to be
mentioned, that all our patients were on glatiramer (copolymer 1,
copaxoneH) for at least 12 months when studied. Glatiramer is
injected daily into adipose tissue. It has been reported that
prolonged treatment with glatiramer leads to localized lipoatro-
phy. [43] Obviously, glatiramer can activate lipolysis, specifically
in adipose tissue.
The strength of our study is that we studied MS patients and
healthy controls closely matched for gender, age, body composi-
tion and physical activity level. Furthermore, MS patients were
comparable with respect to EDSS score and medication.
However, duration of the disease might differ within patients
due to a variable time interval between first outbreak and
diagnosis of the disease. Despite good matching, the sample
number of patients was rather small. Furthermore, systemic and
local markers for inflammation were not determined. Also, we did
not test specifically for autonomic nervous system function. In
future studies, MS patients should also be studied during exercise
after overnight fasting, but without glucose and during graded (0.5
and 0.75 W/kg body weight) exercise intensities to characterize
more precisely lipid mobilization and oxidation and autonomic
dysfunction during exercise.
In summary, MS patients responded with a more highly
increased carbohydrate oxidation rate after an oral glucose load
than healthy controls, both at rest and during exercise at a
moderate work load. At rest, adipose tissue was characterized by a
higher lipolytic activity before and after the glucose load, which
might be caused by either local monocyte/macrophage infiltration
due to systemic inflammation or glatiramer injections into adipose
tissue. Skeletal muscle did not show any signs of mitochondrial
dysfunction.
In conclusion, glucose tolerance is not impaired in MS patients.
At rest, there is no indication for metabolic inflexibility or
mitochondrial dysfunction in skeletal muscle. The increased
adipose tissue lipolytic activity might result from glatiramer
treatment. Autonomic dysfunction might cause dysregulation of
postprandial thermogenesis at rest and of lipid mobilization during
exercise.
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